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What is the place of peritoneal dialysis in the integrated treat-
ment of renal failure? The role of peritoneal dialysis (PD) in renal
replacement therapy (RRT) remains unclear. There are no con-
trolled trials to provide hard evidence of its efficacy. Comparative
studies with haemodialysis from different centres and countries
have given conflicting results even when allowing for case mix.
Data from the United States on patients starting or receiving
treatment in the late 1980s suggested a worse prognosis for older
patients, particularly diabetics receiving PD as compared to HD.
Analysis of the USRDS data base for patients starting in the early
1990s shows an improvement in outcome but with no difference in
overall mortality. The Canadian registry has recently published
data showing a better survival with PD than with HD in the first
two years of RRT. Morbidity is similar with both therapies,
although hospitalization is increased with PD. Unfortunately
long-term technique survival is not as good with PD. However, PD
has certain medical advantages, particularly the maintenance of
residual renal function that contributes to solute and fluid re-
moval. It may also postpone the onset of amyloidosis. Patients
transplanted after previous PD have a decreased risk of early
acute renal failure and equally good long-term results when
compared to those patients who were on HD before transplanta-
tion. The quality of life is as good with PD as with center HD, and
there are social advantages to PD including an increased chance
of employment, more flexible holidays and avoidance of thrice
weekly travel to a dialysis center. PD also has logistical advantages
and can be utilized by the majority of new patients. We therefore
conclude that PD has potential advantages early in the course of
RRT, and should therefore be offered as a first option to all
suitable new patients. Whether PD has a major or minor role in
later years (.5) remains unclear.
More than twenty years after its inception as an accepted
modality of renal replacement therapy (RRT) the place of
peritoneal dialysis (PD) in comparison with hemodialysis
(HD) and transplantation remains unclear. From a 40%
usage in the UK and New Zealand, its acceptance varies
across the world to less than a 6% usage in Japan and
Germany. Careful analysis of patient and technique sur-
vival rates, however, indicates that over the first five years
of RRT, CAPD is as effective as HD and may even offer
certain advantages. We therefore contend that PD should
be considered equally with HD and transplantation as
modes of RRT, and that each of these therapies should be
freely available and used as appropriate by an individual
uremic patient during his or her lifetime as part of an
integrated package of care.
The aim of RRT should be to restore patients to as
normal a level of health as possible and to ensure full social
and physical rehabilitation. None of the available therapies
offers a cure for renal failure and each has its problems.
PD, for instance, can partially replace renal excretory
function but clearly does not in any way substitute for the
normal endocrine activities of the kidney. The challenge for
nephrologists is to use each of the therapies to its greatest
advantage and thus to maximize the quality of care and the
longevity of RRT.
COMPARISON OF OUTCOME WITH
HEMODIALYSIS
The major difficulty in objectively assessing the role of
PD is that there is no randomly allocated prospective trial
comparing the different therapies. As a result, any compar-
isons should be treated with caution and should include as
detailed analysis of the case mix as possible.
The first serious attempt to look at outcome after
correction for confounding variables was made by Burton
and Walls [1], who concluded that on an intention to treat
basis there was no difference in mortality between PD, HD
and transplantation. Subsequently several studies have
been published, and some of these are summarized in
Table 1 [2–7]. As can be seen, PD has been reported to give
better, worse or equal survival to HD, and there are
differences even between those reports that use a case mix
analysis.
The largest study to date was the USRDS analysis, which
looked at 681 PD and 3376 HD patients in 1986 and 1987,
and concluded that outcome was worse for diabetic patients
aged 58 years or older if they were treated with PD [7].
Lunde et al examined the outcome for 308 PD and 1244
HD individuals aged 65 years or older, who started RRT
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from 1980 to 1987 inclusive [8]. Although there was a trend
to a higher mortality in elderly diabetics receiving CAPD,
this was not statistically significant. Using similar method-
ology Vonesh and Moran recently looked at comparative
survival rates for incident HD and PD subjects as recorded
by the USRDS for the years 1989 to 1993 and found no
difference in the overall death rate [9], although there was
a slight increase among female diabetic subjects [10]. These
studies suggest that PD results have improved over time in
the USA.
One study that caused concern is that of Bloembergen et
al [11]. This again used USRDS data but compared prev-
alent patients on January lst of 1987, 1988 and 1989 using
a Poisson regression model. On average, PD subjects had a
19% higher risk of mortality. This was significant for older
patients who were both diabetic [relative risk (RR) 5 1.38,
P , 0.001] and non-diabetic (RR 5 1.11, P , 0.001).
Unfortunately, this report has been interpreted by some
commentators to indicate that PD is a second class therapy
and therefore avoided if possible. Since only prevalent
patients were included, by definition the investigation ex-
cluded those who started and stopped RRT within one
year. This could bias the results towards HD since individ-
uals who were referred late during the course of their
disease tend to receive HD and are known to have a worse
outcome [12]. In addition, the subjects were not a single
cohort but had been receiving RRT for varying lengths of
time. A futher criticism is that the case mix analysis only
considered diabetes and no other co-morbid factors [13].
Finally, previous studies have generally used a Cox model
to analyze the data, making a direct comparison more
difficult.
The mortality of patients on PD in the USA has been
compared to that of similar patients in other countries. In
the CANUSA PD study the mortality rate in the USA
centers was nearly twice that in the Canadian ones [14].
Similarly, patients starting RRT in 1986 and 1987 in
Lombardy did better than those in the USA [15]. This
difference was not explained even when an allowance was
made for demographic and comorbid covariates. These
studies suggest there are factors affecting mortality on PD
in the USA that are not necessarily relevant elsewhere.
Recently a further analysis of the Canadian registry data
suggested that for incident patients, after allowing for
co-morbid factors, age, sex, ethnicity, etc., the survival with
PD was better in the first two years of treatment compared
to HD, with subsequently no difference up to four years
[16]. This conclusion was reached using a Poisson regres-
sion analysis that accounted for treatment modality
switches. In contrast, using a Cox regression model, which
is the technique used by most other registries to date, there
was no significant difference in outcome between the two
types of dialysis on an intention to treat basis. No informa-
tion on dialysis efficiency, such as, Kt/V values, was pro-
vided, so it remains possible–although unlikely–that the
HD patients were relatively underdialyzed. One study has
suggested that when HD and PD patients receive equiva-
lent amounts of dialysis they have the same outcome [17].
As can be seen from the above, the conclusion reached
from examining registry data can be affected by the method
of analysis. It should also be noted that because informa-
tion concerning large numbers of individuals is being
assessed, small differences can be statistically significant.
For instance, if PD has a RR of 1.1 compared to HD and
the mortality rate for the latter is 20% over a certain period
of time, this means that for PD the rate will be 22%. The
relevance of this difference to the individual patient is
unclear, particularly when other issues such as quality of
life are taken into consideration. The consensus view is that
the differences between the results coming from the various
registries are due at least in part to unmeasured variations
in case mix, such as the relative severity of different
comorbid conditions [18]. The reasonable conclusion from
all this information is that mortality is the same for HD and
PD when comparing identical types of patients, at least for
the first few years of RRT. It should be acknowledged,
however, that this conclusion may not have been derived
from a comparison with the best possible results. To date
the highest rate of survival with HD is apparently that
reported by the unit in Tassin [19]. It is not clear how
universal their results are, nor whether there was any
patient selection in Tassin, but certainly no one has ever
claimed as good an outcome with PD.
With respect to morbidity, Maiorca and Cancarini made
a detailed survey of the literature and concluded that there
was little difference between PD and HD [20]. One indirect
marker of morbidity is hospitalization. Table 2 summarizes
the more recently published findings [21–26]. It is clear that
hospitalization is more likely to be necessary with PD than
HD. Burton and Walls noted that the difference decreased
Table 1. Survival comparisons: Hemodialysis versus peritoneal dialysis
Study Reference Year Outcome
Maiorca [2] 1991 CAPD better in elderly
Piedmont [3] 1995 No difference
Canada [4] 1995 CAPD better
Lombardy [5] 1995 CAPD worse
Australia [6] 1995 CAPD worse
USRDS [7] 1994 CAPD worse for elderly diabetics
Table 2. Comparison of hospitalization
Author Reference Year N Increased with PD
Burton [21] 1989 227 Yes
Serkes [22] 1990 657 Only diabetics
William [23] 1990 58 Yes, elderly
Singh [24] 1992 40 No
Maiorca [25] 1993 494 Yes
Habach [26] 1995 221301 Yes
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with time, and others have claimed that if episodes of
peritonitis are not considered then there is no significant
difference [21].
One consideration when offering PD as an effective form
of RRT is how long treatment can continue. There is little
doubt that technique survival is usually shorter with CAPD
than HD. As evidence for this statement it is the fact that
there are relatively few patients who have had more than 10
years of continuous treatment with PD as compared to HD.
Despite this finding, the Italian cooperative PD study
reported a technique survival of 62% at four years and 48%
at eight years [27]. Our own data in comparison to HD
show no difference in technique survival at four years, but
then show an increasing difference in favor of HD up to
eight years. One difficulty with analyzing technique survival
is that death on PD is regarded as lost to follow up. It is
possible that this may give an over-optimistic result, as it
could be argued that it does not take account of the fact
that death may have been related to inadequate treatment,
for example, under-dialysis or fluid overload.
POSSIBLE ADVANTAGES OF PERITONEAL
DIALYSIS
There are possible medical advantages to be gained from
using PD. It is well recognized that residual renal function
(RRF) is better preserved during PD than HD [28]. RRF is
of considerable benefit to the dialysis patient. In their long
term study, Faller and Lameire demonstrated that the loss
of clearance over time in patients on PD was related to the
decline in RRF rather than to a decrease in membrane
function [29]. Thus, RRF makes a significant contribution
to total clearance and to the maintenance of fluid balance.
It allows the patient a more liberal diet/fluid intake and
may delay the onset of dialysis-related amyloidosis [30],
though this has recently been questioned [32]. RRF, rather
than peritoneal clearance, both at baseline and over time, is
a major factor contributing to survival of PD patients [32].
When the difference in loss of RRF was described, most, if
not all, of the HD patients were being treated with cu-
prophane or other relatively bio-incompatible dialyzers. A
recent, small, randomly allocated trial has suggested that
the use of a polysulfone membrane is associated with better
preservation of RRF as compared to cuprophane [33].
There are no published data comparing whether the de-
cline in the RRF is the same as that which occurs with PD
when using polysulfone or a similar membrane. It is also
interesting to note that one report has suggested that RRF
lasts longer on CAPD than on automated peritoneal dial-
ysis (APD) [34]. If PD is to be successful, efforts clearly
need to be made to preserve RRF, such as avoiding
nephrotoxic antibiotics [35] and possibly using a loop
diuretic. This may not preserve RRF with regards to
clearance, but may improve fluid balance. It is noteworthy
that in the study of Faller and Lameire, urine volume was
greater in the Colmar patients as compared to those
treated in Gent and significantly more patients of the
former group were taking a loop diuretic [29].
As with HD, any complication of uremia can occur
during PD treatment, though on average PD patients have
a higher hemoglobin concentration. Since recombinant
erythropoietin is now available this difference has become
an economic rather than a medical advantage.
It has been suggested that PD patients may have better
cognitive function than those receiving HD. Garcia-Maldo-
nado, Williams and Smith reported that those individuals
receiving CAPD had a better mental performance [36].
There was, however, a significantly higher hematocrit (34.4)
in the PD group compared with HD subjects (28.4) and it
has been shown that treatment of anemia with recombinant
human erythropoietin improves cognitive function [37, 38].
Thus, in the absence of a randomly allocated prospective
trial or a very large cohort observation in which confound-
ing variables such as comorbidity and hemoglobin concen-
tration can be eliminated, this possible benefit of PD
remains unproven.
For many patients the ultimate goal is a successful
transplant. Bleyer et al have recently suggested that PD
patients may have better outcomes in the first week after
cadaveric renal transplantation than do HD patients [39].
In particular, they were less likely to need postoperative
dialysis. The authors speculated that this might be due to
greater antigenic stimulation during HD. An alternative
possibility is that PD subjects are less likely to get postop-
erative acute renal failure since they are more likely to be
well hydrated [30]. Van Loo et al compared transplant
outcomes for 117 patients who had previously been on
CAPD to 117 individuals who had had prior HD [40].
Delayed graft function requiring dialysis postoperatively
occurred in 27 of the PD and 59 of the HD patients (P ,
0.0001), though there were no differences in mean serum
creatinine at six weeks or six months. Similar results have
been reported by the Australia and New Zealand Registry
(Grabin, personal communication). Maiorca et al, in con-
trast, found no difference in incidence or length of delayed
graft function when comparing the previous type of RRT
[41]. Long-term graft survival, however, is the same irre-
spective of the previous mode of dialysis [41]. It is also
claimed that the relatively improved RRF of PD makes it
easier to perform the uretero-vesical anastomosis, reducing
the chances of leaks, etc., since the bladder will be less
contracted. However, there is no detailed analysis of post-
transplant urological complications in relation to the pre-
vious mode of dialysis. There are also other distinct advan-
tages in proceeding to a graft from PD in contrast to HD
[42]. For instance, since PD is a home therapy there is
considerably less risk of acquiring a blood borne virus such
as hepatitis C. With the advent of erythropoietin, however,
the greater risk of antigen sensitization as a result of blood
transfusion during HD (because of the lower average
hemoglobin) should have disappeared. There remains the
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possibility that for highly sensitized individuals PD could
have an advantage because there is less risk of inadvertent
blood loss requiring a transfusion [42].
The original study by Burton and Walls suggested that
after allowing for case mix, survival was equally good on an
intention to treat basis irrespective of the mode of RRT,
including renal transplantation [1]. This latter finding has
recently been challenged by the findings of Edwards,
Bennett and Cecka, who looked at the outcome of patients
established on the transplant waiting list and thus presum-
ably those with the same relatively low prevalence of
co-morbid factors [43]. They compared survival in those
who were transplanted to those who remained on dialysis.
Although there was an early small increase in mortality
after transplantation, within less than one year after the
operation survival was better for those with a new kidney as
compared to patients remaining on dialysis. This difference
occurred even if there were three to six mismatches. This
study did not distinguish between PD and HD patients on
the waiting list. If confirmed, these results suggest that a
transplant is the best RRT in terms of survival. Maiorca et
al found that patients on the transplant waiting list had the
same survival whatever the type of dialysis being used [41].
QUALITY OF LIFE WITH RENAL REPLACEMENT
THERAPY
Since by definition RRT must be life long, it is important
to consider not only crude survival but also the quality of
life the various therapies offer. Again, there are no ran-
domly allocated controlled trials but there is broad consen-
sus that transplantation gives the best quality of life [44, 45].
This conclusion is justified by the fact that patients act as
their own controls and report a substantial improvement
after a successful graft. Comparisons of PD with HD must
be treated with considerable caution. The studies that are
available, however, suggest PD gives an equally good and
possibly a better quality of life [46–50]. There are certainly
advantages of PD, including the fact that it is a home
treatment that avoids repeated visits to the dialysis unit.
Holidays and travel are more flexible since the individual is
not confined to certain geographical areas where there is a
renal unit. CAPD potentially allows the patients to have
more control over their own lives and should provide more
chance of rehabilitation [42]. There are reports suggesting
that individuals receiving PD are more likely to be em-
ployed than with HD [51, 52]. Woods et al reported that
patients trained to do self-care HD at home or in a center
had a significantly lower mortality than those cared for by
professional staff, even when factors such as comorbidity
were included in the analysis [53]. This suggests that some
form of home treatment should be encouraged and clearly
PD is ideal in this respect. Unfortunately, as noted above,
no such clear advantage in terms of survival has been
reported for PD in comparison with center HD. The better
result with self-care HD may be due to a selection bias in
choosing patients for this type of RRT, which includes
psychological factors such as compliance, mental stability
and intelligence. No analysis to date has been able to assess
these variables.
De Vecchi et al have published an interesting survey of
120 patients who had experienced both PD and HD for at
least six months with transfers in either direction [54]. Since
the usual reason for a change was a problem occurring with
the initial therapy, most subjects preferred their current
treatment at the time of asking. There were no marked
differences overall between the two therapies when the
reasons for their preference were assessed. One further way
of assessing the impact of RRT is to assess the illness
intrusiveness, which measures the degree to which the
illness interferes with lifestyle, activities and interests [55].
When the three types of RRT were compared, only renal
transplantation had significantly less impact. There were no
differences between the various types of dialysis [55].
Though PD is theoretically a self-supervised treatment, in
practice a carer is often involved. A small study in Cardiff
found that the caregivers of home HD patients found the
actual therapy stressful, but those involved with PD subjects
thought the treatment was time consuming and tedious
(Salek, personal communication). Maiorca commented
that after a number of years there may be burn out of either
the patient and/or caregiver [56]. As patients age, there
may come a point in time when he or she is no longer able
to do this procedure.
LOGISTICAL ADVANTAGES OF PERITONEAL
DIALYSIS
There are a number of logistical advantages of PD. Since
all health care systems are under financial pressure, PD
does allow expansion with limited resources and avoids a
major capital program [42]. This policy occurred by default
in the UK during the 1980s. PD certainly requires a lower
staff:patient ratio than center HD, and standard CAPD is
cheaper. It is not yet clear whether measures designed to
improve adequacy, such as APD with its daytime bags, have
a cost advantage, at least over self-care HD.
FACTORS INFLUENCING THE CHOICE OF
PERITONEAL DIALYSIS
One further consideration is whether there are any
medical reasons for strongly recommending HD or PD.
Hamburger et al have published a suggested list showing
that the large majority of patients can be considered for PD
[57]. For some individuals PD is clearly preferred. These
include those with problems with vascular access, small
children, those who live a long distance from the dialysis
center, those with complications from HD, and those with
a strong desire for independence and autonomy. It can also
been argued that in the absence of a live-related kidney
transplant donor, it is preferable to begin RRT with PD
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since in addition to all the possible advantages noted
previously, it may delay the use of blood access sites.
One factor that influences whether or not a patient is
treated by PD is the time of referral. Patients referred early
in their disease to a renal unit are more likely to choose PD.
Those who are referred late, particularly if they need
emergency dialysis, usually opt to stay on HD [58, 59].
Despite all the reasons given above, the use of PD varies
widely throughout the world. Nissenson et al have given a
cogent review of the non-medical factors that impact on
RRT selection, and clearly imply that in some centers the
patients are denied an effective form of therapy [60].
ROLE OF PERITONEAL DIALYSIS IN RENAL
REPLACEMENT THERAPY
In view of the evidence it is reasonable to conclude that
PD is equally as good, if not better than HD, as an initial
form of RRT and is acceptable to many patients. Further-
more, reviewing the literature it is reasonable to draw the
conclusion that if medically suitable, PD should be the first
option for RRT (in the absence of a suitable live donor)
when a patient reaches end-stage renal failure. The benefits
as noted previously include preservation of RRF, a possible
delay in the onset of amyloidosis, better early survival,
reduced risk of being infected by a blood borne virus and
better short-term results with a transplant. One could thus
argue that all medically suitable patients should be encour-
aged (but not coerced) to start with PD. This suggestion is
made because Szabo et al have shown that when freedom of
choice was withdrawn, the patients’ quality of life as judged
by mental scores became significantly worse [61], though no
changes were seen in physical scales. We therefore suggest
a schema for managing patients with end-stage renal dis-
ease that is depicted in Figure 1.
As a result of the foregoing analysis, one is led to a
number of propositions: (1) patients should have a free
choice, assuming the appropriate resources are available;
(2) physicians should offer all three types of RRT; (3) it is
likely that each form of therapy may have a role to play
during the lifetime of patients with renal failure. Further-
more, one should no longer be attempting to prove that one
form of dialysis is better than another, but rather identify
ways in which the differing modalities complement each
other. In this respect it is interesting to note the recent
report by Van Biesen et al suggesting that patients starting
on PD and then switched to HD had better survival than
those remaining on their initial treatment of either type
[62].
There still remains, however, the unsolved question of
whether PD can be used by the majority of subjects after
several years of RRT. Foley et al have suggested that
during the first two years of RRT there is no difference in
mortality comparing PD to HD, but subsequently it is
increased in PD patients [63]. The answer will almost
certainly depend on how easy it will be in practice to
augment solute clearance and fluid removal (to replace
RRF) without adversely affecting the patients’ quality of
life. It is worth noting the report of McComb et al [64], who
found no improvement in quality of life when patients were
switched from CAPD to APD, and thankfully there was no
decline either.
One can therefore conclude that PD should be freely
available as part of an integrated RRT program. PD is a
clear option for the majority of patients needing RRT early
in the course of their disease. PD should be an option for
increasing numbers of patients after five years or more of
RRT, but the size of such a population remains yet
uncertain.
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